

## SUPPLEMENTARY TABLES

**Supplementary Table 1:** Sensitivity analysis of 1-year overall survival results.

Study	Pooled prevalence	LCI 95%	HCI 95%
Iwazawa 2012 <sup>[20]</sup>	93.7	83.8	99.5
Choi 2017 <sup>[23]</sup>	91.9	83.4	97.6
Lee 2019 <sup>[18]</sup>	94.5	86.3	99.4
Miyayama 2021 <sup>[21]</sup>	91.6	79.5	98.9
Bannangkoon 2021 <sup>[17]</sup>	96.2	89.7	99.8

LCI: Lower confidence interval, HCI: Higher confidence interval

**Supplementary Table 2:** Sensitivity analysis of 3-year overall survival results.

Study	Pooled prevalence	LCI 95%	HCI 95%
Iwazawa 2012 <sup>[20]</sup>	68.8	40.9	91.5
Choi 2017 <sup>[23]</sup>	65.6	39.9	87.5
Lee 2019 <sup>[18]</sup>	68.3	40.8	90.8
Miyayama 2021 <sup>[21]</sup>	60.8	31.4	86.8
Bannangkoon 2021 <sup>[17]</sup>	80.3	72.8	86.8

LCI: Lower confidence interval, HCI: Higher confidence interval

**Supplementary Table 3:** Sensitivity analysis of overall recurrence rate.

Study	Pooled prevalence	LCI 95%	HCI 95%
Iwazawa 2012 <sup>[20]</sup>	60.2	16.9	96.6
Bannangkoon 2021 <sup>[17]</sup>	40.7	22.3	60.5
Miyayama 2013 <sup>[19]</sup>	66.0	26.2	96.9
Miyayama 2014 <sup>[24]</sup>	69.7	31.2	97.9

LCI: Lower confidence interval, HCI: Higher confidence interval